Sign Out
Pregnancy: There is no or limited data from the use of rifaximin in pregnant women.
Animal studies showed transient effects on ossification and skeletal variations in the foetus (see Pharmacology: Toxicology: Preclinical safety data under Actions).
As a precautionary measure, use of rifaximin during pregnancy is not recommended.
Breastfeeding: It is unknown whether rifaximin/metabolites are excreted in human milk.
A risk to the breast-fed child cannot be excluded.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from rifaximin therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Fertility: Animal studies do not indicate direct or indirect harmful effects with respect to male and female fertility.
Continue with Google